Back
Innate Pharma SA Quote, Financials, Valuation and Earnings
Sponsored
IPHA
Sponsored
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
29
IPHA
Innate Pharma SA
Last Price:
1.67
Seasonality Move:
8.67%
7 Day Trial
ALL ACCESS PASS
$
7
Start Investing Smarter Unlock Louis Navellier's Stock Grader for free
Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.Innate Pharma SA Price Quote
$1.67
-0.02 (12.08%)
(Updated: November 21, 2024 at 5:13 AM ET)
Innate Pharma SA Key Stats
Sell
29
Innate Pharma SA (IPHA)
is a Sell
Day range:
$1.60 - $1.70
52-week range:
$1.29 - $3.15
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.62
P/B ratio:
4.01%
Volume:
6.4K
Avg. volume:
11K
1-year change:
-32.85%
Market cap:
$123.9M
Revenue:
$56.2M
EPS:
$-0.45
How Much Does Innate Pharma SA Make?
-
How Much Are Innate Pharma SA's Sales Annually?
IPHA Revenues are $56.2M -
How Much Profit Does Innate Pharma SA's Make A Year?
IPHA net income is -$8.2M
Is Innate Pharma SA Growing As A Company?
Data Unavailable
Innate Pharma SA Stock Price Performance
-
Did Innate Pharma SA Stock Go Up Last Month?
Innate Pharma SA share price went down by -17.17% last month -
Did IPHA's Share Price Rise Over The Last Year?
IPHA share price fell by -32.85% over the past 1 year
What Is Innate Pharma SA 52-Week High & Low?
-
What Is Innate Pharma SA’s 52-Week High Share Price?
Innate Pharma SA has traded as high as $3.15 over the past 52 weeks -
What Is Innate Pharma SA’s 52-Week Low Share Price?
Innate Pharma SA has traded as low as $1.29 over the past 52 weeks
Innate Pharma SA Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Innate Pharma SA?
-
How Much Debt Does Innate Pharma SA Have?
Total long term debt quarterly is $38.1M -
How Much Cash Does Innate Pharma SA Have?
Cash and short term investments quarterly total is $98.4M -
What Is Innate Pharma SA’s Book Value Per Share?
Book value per share is 0.38
Is Innate Pharma SA Cash Flow Positive?
-
What Is IPHA Cash Flow From Operations?
Cash flow from operations (TTM) is -$19.4M -
What Is Innate Pharma SA’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$5.4M -
What Is Innate Pharma SA’s Cash Flow From Investing?
Cash flow from investing (TTM) is $23.5M
Innate Pharma SA Return On Invested Capital
-
Is Management Doing A Good Job?
IPHA return on invested capital is -39.78% -
What Is Innate Pharma SA Return On Assets?
ROA measures how assets are converting to revenues and is -18.89% -
What Is IPHA Return On Equity?
ROE is a measure of profitability and is -72.79%
Innate Pharma SA Earnings Date & Stock Price
-
What Is Innate Pharma SA's Stock Price Today?
A single share of IPHA can be purchased today for 1.69 -
What Is Innate Pharma SA’s Stock Symbol?
Innate Pharma SA trades on the nasdaq under the ticker symbol: IPHA -
When Is Innate Pharma SA’s Next Earnings Date?
The next quarterly earnings date for Innate Pharma SA is scheduled on March 21, 2025 -
When Is IPHA's next ex-dividend date?
Innate Pharma SA's next ex-dividend date is November 21, 2024 -
How To Buy Innate Pharma SA Stock?
You can buy Innate Pharma SA shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Innate Pharma SA Competitors
-
Who Are Innate Pharma SA's Competitors?
Below is a list of companies who compete with Innate Pharma SA or are related in some way:
Innate Pharma SA Dividend Yield
-
What Is IPHA Dividend Yield?
Innate Pharma SA’s dividend yield currently is 0% -
What Is Innate Pharma SA’s Payout Ratio?
Innate Pharma SA’s payout ratio is 0% -
When Did Innate Pharma SA Last Pay A Dividend?
The latest dividend pay date is November 21, 2024 -
What Is Innate Pharma SA’s Dividend Per Share?
Innate Pharma SA pays a dividend of $0.00 per share
Innate Pharma SA Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 0% |
Revenue: | 0% | 0% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 7.40 |
Upside from Last Price: | 339.04% |